The current price of NBIX is $166.05 — it has increased by 0.73% since the previous close. Data as of Nov 4, 2026.
NBIX is up 12.86% over the past week, up 15.97% over the past month and up 15.96% over the past year. The price is above its 200-day moving average of $147.60.
Analysts' average 12-month price target for NBIX is $204.89, which implies 23.39% upside from the current price. Individual estimates range from $165.00 to $230.00.
Of the 29 analysts covering Neurocrine Biosciences, Inc., 4 rate it a strong buy, 21 rate it a buy and 4 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Neurocrine Biosciences, Inc. has a market capitalization of $16.81B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Neurocrine Biosciences, Inc. posted earnings of $3.29 per share against an estimate of $1.91, beating expectations by 72.25%. Upcoming reports are listed in the earnings calendar.
Neurocrine Biosciences, Inc. reported revenue of $1.12B in its most recent quarter, which has increased by 41.24% compared with the same quarter a year earlier. Analysts had expected $1.04B.
Neurocrine Biosciences, Inc. has not paid any dividends over the past year.
In the latest trading session NBIX moved between $162.03 and $169.02, a range of 4.21% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Neurocrine Biosciences, Inc. shows a buy rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks NBIX has traded between $122.14 and $186.12. The current price is 10.78% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.